ARTICLE | Clinical News
XOMA 052 regulatory update
August 9, 2010 7:00 AM UTC
The COMP issued a positive opinion to grant Orphan Drug designation to Xoma's XOMA 052 to treat Behcet's disease. The humanized IgG2 mAb against IL-1 beta is in Phase II testing for the indication. CO...